Replies to post #40311 on OncoSec Medical Inc (ONCSQ)

[lasers]

$ONCS results is everything we had hoped for and more!. BORR 50%

OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma PatientsData from Recently Completed Phase 2 Monotherapy and Combination Therapy Studies